Department of Pediatrics, Nutrition and Metabolic Diseases, The Children's Memorial Health Institute, Warsaw, Poland.
Institute of Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
Orphanet J Rare Dis. 2019 Feb 22;14(1):55. doi: 10.1186/s13023-019-1029-1.
Acid sphingomyelinase deficiency (ASMD), due to mutations in the sphingomyelin phosphodiesterase 1 (SMPD1) gene, is divided into infantile neurovisceral ASMD (Niemann-Pick type A), chronic neurovisceral ASMD (intermediate form, Niemann-Pick type A/B) and chronic visceral ASMD (Niemann-Pick type B). We conducted a long-term observational, single-center study including 16 patients with chronic visceral ASMD.
12 patients were diagnosed in childhood and 4 others in adulthood, the oldest at the age of 50. The mean time of follow-up was approximately 10 years (range: 6 months - 36 years). Splenomegaly was noted in all patients at diagnosis. Hepatomegaly was observed in 88% of patients. Moderately elevated (several-fold above the upper limit of normal values) serum transaminases were noted in 38% of patients. Cherry-red spots were found in five Gypsy children from one family and also in one adult Polish patient, a heterozygote for p.delR610 mutation. Dyslipidemia was noted in 50% of patients. Interstitial lung disease was diagnosed in 44% of patients. Plasmatic lysosphingomyelin (SPC) was elevated in all the patients except one with p.V36A homozygosity and a very mild phenotype also presenting with elevated plasmatic SPC-509 but normal chitotriosidase activity. The most common variant of SMPD1 gene was p.G166R. We found a previously unreported variant in exon 2 (c.491G > T, p.G164 V) in one patient.
Chronic visceral ASMD could constitute a slowly progressing disease with a relatively good outcome. The combined measurement of lysosphingomyelin (SPC) and lysospingomyelin-509 (SPC-509) is an essential method for the assessment of ASMD course.
酸性鞘磷脂酶缺乏症(ASMD)是由于鞘磷脂磷酸二酯酶 1(SMPD1)基因突变引起的,可分为婴儿神经内脏型 ASMD(尼曼-皮克病 A 型)、慢性神经内脏型 ASMD(中间型,尼曼-皮克病 A/B 型)和慢性内脏型 ASMD(尼曼-皮克病 B 型)。我们进行了一项长期观察性、单中心研究,纳入了 16 例慢性内脏型 ASMD 患者。
12 例患者在儿童期确诊,4 例在成年期确诊,年龄最大者为 50 岁。平均随访时间约为 10 年(范围:6 个月-36 年)。所有患者在诊断时均有脾肿大。88%的患者有肝肿大。38%的患者血清转氨酶中度升高(高于正常值上限数倍)。在一个吉普赛家庭的 5 个孩子和一个波兰成年杂合子患者(p.delR610 突变)中发现了樱桃红斑。50%的患者有血脂异常。44%的患者诊断为间质性肺病。除 1 例 p.V36A 纯合子和 1 例表型非常轻微、也有血浆 SPC-509 升高但组织胺三糖苷酶活性正常的患者外,所有患者的血浆溶血磷脂酰胆碱(SPC)均升高。SMPD1 基因最常见的变异是 p.G166R。我们在 1 例患者中发现了一个以前未报道的外显子 2 变异(c.491G>T,p.G164V)。
慢性内脏型 ASMD 可能是一种进展缓慢、预后较好的疾病。溶血磷脂酰胆碱(SPC)和溶血磷脂酰胆碱-509(SPC-509)的联合测量是评估 ASMD 病程的重要方法。